hALK.CAR T cells / Boston Children's Hospital - LARVOL DELTA

Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives. (PubMed, Front Immunol) - "Therefore, ALK-directed immunotherapies represent biologically rational and promising approaches that may, if proven safe and effective in clinical trials, address resistance and improve long-term disease control. In this review, we will discuss ALK-specific immunotherapies, including ALK vaccines, ALK CAR-T and other cellular therapies, as well as ALK-targeting antibodies with a particular focus on pediatric ALK-positive tumors."

Journal • Review • Neuroblastoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • Solid Tumor • Transplantation • ALK

ALK expression identifies a therapeutically targetable subset of Merkel cell carcinomas responsive to ALK.CAR-T cell therapy alone or in combination with ALK inhibitors (AACR 2026) - P1/2 | "We identified ALK as a clinically relevant target in MCC and demonstrated that ALK.CAR-T cells, especially when combined with ALK inhibitors, have a potent anti-tumor activity against ALK+ MCC. Our study provides a preclinical rationale for expanding the ongoing Phase I/II clinical trial in relapsed/refractory neuroblastoma patients to include patients with MCC, thus broadening the therapeutic indication of ALK.CAR-T."

CAR T-Cell Therapy • Combination therapy • IO biomarker • Endocrine Cancer • Merkel Cell Carcinoma • Neuroblastoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor • ALK • GZMB • IFNG

ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells (AACR 2024) - "These findings provide insights into the potential of ALK.CAR-T cells as a novel therapeutic strategy for neuroblastoma. A Phase I clinical trial to test ALK.CAR-T cells in combination with ALK TKIs in children with refractory/relapsed neuroblastoma is being implemented based on these results."

CAR T-Cell Therapy • IO biomarker • Neuroblastoma • Oncology • Solid Tumor • ALK

ALK.CAR-T Cells as a New Potential Treatment for ALK+ Merkel Cell Carcinoma (SITC 2025) - P1/2 | "(B) ALK and GD2 expression by FACS (C) MCC cell lines (ALK IHC) (D) Killing assay (E) Killing assay (neladalkib N or lorlatinib L). (B) Kaplan-Meier survival analysis (relative to A) (C) MKL1 tumor progression. (D) Kaplan-Meier survival analysis (relative to C)"

CAR T-Cell Therapy • IO biomarker • Endocrine Cancer • Merkel Cell Carcinoma • Neuroblastoma • Neuroendocrine Tumor • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor • ALK • GZMB • IFNG

ALK.CAR-T cells as a new potential treatment for ALK+Merkel cell carcinoma (AACR-NCI-EORTC 2025) - P1/2 | "For in vivo testing, NSG mice were injected intravenously with human MCC cell lines and, after engraftment, treated with ALK.CAR-T cells, either alone or in combination with the ALK inhibitor lorlatinib. We identified ALK as a clinically relevant target in MCC and demonstrated that ALK.CAR-T cells, especially when combined with ALK inhibitors, have a potent anti-tumor activity against ALK+ MCC. Our study provides a preclinical rationale for expanding the ongoing Phase I/II clinical trial in relapsed/refractory neuroblastoma patients to include patients with MCC, thus broadening the therapeutic indication of ALK.CAR-T."

CAR T-Cell Therapy • IO biomarker • Endocrine Cancer • Merkel Cell Carcinoma • Neuroblastoma • Neuroendocrine Tumor • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor • ALK • GZMB • IFNG